FDA Approves New Oral Therapy for High‑Risk Tenosynovial Giant Cell Tumor

The FDA has approved the small‑molecule inhibitor pimicotinib (brand name Pimjetmi) for selected patients with symptomatic tenosynovial giant cell tumor (TGCT) who face a high surgical risk. This oral selective inhibitor of colony‑stimulating factor provides a non‑surgical treatment option for this rare benign soft‑tissue tumor.

Source link